| Literature DB >> 18022555 |
Medina C Kushen1, Adam M Sonabend, Maciej S Lesniak.
Abstract
Immunotherapy has emerged as a promising tool in the management of malignant central nervous system tumors. Despite improvement in patient survival, traditional approaches, which consist mostly of surgery, radiotherapy, and chemotherapy, have been largely unsuccessful in permanently controlling these aggressive tumors. Immunotherapeutic strategies offer not only a novel approach but also an advantage in a way other modalities have been failing. Specifically, the capabilities of the immune system to recognize altered cells while leaving normal cells intact offer tremendous advantage over the conventional therapeutic approaches. This article summarizes our current understanding of immunotherapeutic treatment modalities used in clinical trials for management of malignant central nervous system tumors.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18022555 PMCID: PMC2173874 DOI: 10.1016/j.soc.2007.07.003
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN: 1055-3207 Impact factor: 3.495